At the ACC, Novartis presented that in two analyses—one in patients with chronic kidney disease and the other in diabetes—canakinumab "substantially" reduced the risk of major adverse cardiovascular events.  I realize that the MoA is different than apabetalone in that it's a monoclonal antibody targeting interleukin 1-beta, but it sure is an attention grabber.  I  believe they also presented some preliminary findings last year at ESC on the CANTOS trial.  Would be nice of RVX got a bit of this media coverage. 

https://www.fiercepharma.com/pharma/acc-novartis-canakinumab-cuts-cv-risks-patients-kidney-disease-diabetes?mkt_tok=eyJpIjoiTURKalpUUXlZV1ZtWW1KaCIsInQiOiJ1WmtENjdvdUlCcWxXWUdqV1MwTG5UWGhnRmxVWFRtUXk2NWhtUytUNDdwQ0ZjSmp4ZTdUVGZxYkJJelRHVXhqSWVBdzlkMVI0b3dkaUlLbUZmZlM3bFJmZW42b3RLQzBNNFM2VTYyUDljTUlHazFTWk54UXd3cFwvMzBKRTlvVTgifQ%3D%3D&mrkid=9803146

masila